Patent intelligence · US
US 12247052
CpG amphiphiles and uses thereof
CpG amphiphiles and uses thereof
Patent details — US 12247052
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 11, 2025
- Expiration
- Mar 6, 2045
- Applicant
- Elicio Therapeutics, Inc.
- Claims
- 14
- CPC classes
- A61K, A61K2039/555, A61K2039/55561, A61K2039/6018
Quick answer
US 12247052 (CpG amphiphiles and uses thereof) is held by Elicio Therapeutics, Inc.. Status: granted. Granted Mar 11, 2025. Expires Mar 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Elicio Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K2039/555, A61K2039/55561, A61K2039/6018, A61K2039/627, A61K38/00
More from Elicio Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12247052?
US 12247052 (CpG amphiphiles and uses thereof) is held by Elicio Therapeutics, Inc.. Status: granted. Granted Mar 11, 2025. Expires Mar 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12247052?
Elicio Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 12247052 expire?
Our index shows an expiration date of Mar 6, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.